Disease Glycomics Team, Systems Glycobiology Research Group, RIKEN-MAX Planck Joint Research Center for Systems Chemical Biology, Global Research Cluster, RIKEN, Saitama 351-0198, Japan.
J Neurosci. 2013 Jun 12;33(24):10037-47. doi: 10.1523/JNEUROSCI.3137-12.2013.
In demyelinating diseases such as multiple sclerosis, a critical problem is failure of remyelination, which is important for protecting axons against degeneration and restoring conduction deficits. However, the underlying mechanism of demyelination/remyelination remains unclear. N-acetylglucosaminyltransferase-IX (GnT-IX; also known as GnT-Vb) is a brain-specific glycosyltransferase that catalyzes the branched formation of O-mannosyl glycan structures. O-Mannosylation of α-dystroglycan is critical for its function as an extracellular matrix receptor, but the biological significance of its branched structures, which are exclusively found in the brain, is unclear. In this study, we found that GnT-IX formed branched O-mannosyl glycans on receptor protein tyrosine phosphatase β (RPTPβ) in vivo. Since RPTPβ is thought to play a regulatory role in demyelinating diseases, GnT-IX-deficient mice were subjected to cuprizone-induced demyelination. Cuprizone feeding for 8 weeks gradually promoted demyelination in wild-type mice. In GnT-IX-deficient mice, the myelin content in the corpus callosum was reduced after 4 weeks of treatment, but markedly increased at 8 weeks, suggesting enhanced remyelination under GnT-IX deficiency. Furthermore, astrocyte activation in the corpus callosum of GnT-IX-deficient mice was significantly attenuated, and an oligodendrocyte cell lineage analysis indicated that more oligodendrocyte precursor cells differentiated into mature oligodendrocytes. Together, branched O-mannosyl glycans in the corpus callosum in the brain are a necessary component of remyelination inhibition in the cuprizone-induced demyelination model, suggesting that modulation of O-mannosyl glycans is a likely candidate for therapeutic strategies.
在脱髓鞘疾病(如多发性硬化症)中,一个关键问题是髓鞘再生失败,这对于保护轴突免受变性和恢复传导缺陷非常重要。然而,脱髓鞘/髓鞘再生的潜在机制仍不清楚。N-乙酰氨基葡萄糖基转移酶-IX(GnT-IX;也称为 GnT-Vb)是一种脑特异性糖基转移酶,催化 O-甘露糖基聚糖结构的分支形成。α- dystroglycan 的 O-甘露糖化对于其作为细胞外基质受体的功能至关重要,但它的分支结构(仅在大脑中发现)的生物学意义尚不清楚。在这项研究中,我们发现 GnT-IX 在体内形成了受体蛋白酪氨酸磷酸酶 β(RPTPβ)上的分支 O-甘露糖基聚糖。由于 RPTPβ 被认为在脱髓鞘疾病中发挥调节作用,因此对 GnT-IX 缺陷小鼠进行了铜诱导脱髓鞘实验。铜诱导 8 周逐渐促进了野生型小鼠的脱髓鞘。在 GnT-IX 缺陷小鼠中,在治疗 4 周后胼胝体的髓鞘含量减少,但在 8 周时明显增加,表明 GnT-IX 缺乏时增强了髓鞘再生。此外,GnT-IX 缺陷小鼠胼胝体中的星形胶质细胞激活明显减弱,寡突胶质细胞谱系分析表明更多的少突胶质前体细胞分化为成熟的少突胶质细胞。总之,大脑胼胝体中的分支 O-甘露糖基聚糖是铜诱导脱髓鞘模型中髓鞘再生抑制的必要组成部分,这表明调节 O-甘露糖基聚糖可能是一种有前途的治疗策略。